WT1 and acute myeloid leukemia: The nephroblastoma 1 (WT1) antigen is overexpressed in more than 90% of AML, Intellia's investigational therapy, NTLA‐5001 (NCT05066165), is a T‐cell therapy targeting WT1 for the treatment of AML.